The U.S. Court of Appeals for the Federal Circuit found Orexo’s long term Zubsolv patent US 8,940,330 to be valid, and reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016. The ‘330 patent expires in 2032. The decision was rendered in the patent litigation alleging that Actavis’s—a unit of Teva Pharmaceutical—generic Zubsolv…